Coastlands Capital Lp Acquires 25,000 Shares of Adial Pharmaceuticals (NASDAQ:ADIL) Stock

Posted by on Jul 3rd, 2026

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Free Report) major shareholder Coastlands Capital Lp purchased 25,000 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were acquired at an average price of $2.60 per share, for a total transaction of $65,000.00. Following the purchase, the insider owned 373,322 shares in the company, valued at $970,637.20. The trade was a 7.18% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Adial Pharmaceuticals Trading Up 3.2%

ADIL stock opened at $2.90 on Friday. Adial Pharmaceuticals, Inc. has a 1 year low of $1.31 and a 1 year high of $18.90. The company has a fifty day simple moving average of $2.14 and a 200 day simple moving average of $3.10. The firm has a market cap of $6.21 million, a PE ratio of -0.36 and a beta of 1.43.

Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) last posted its earnings results on Friday, May 8th. The company reported ($1.48) EPS for the quarter, topping the consensus estimate of ($2.73) by $1.25.

Analysts Set New Price Targets

Several research firms recently weighed in on ADIL. Loop Capital set a $6.00 target price on Adial Pharmaceuticals in a report on Monday, June 15th. Brookline Capital Markets downgraded Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Needham & Company LLC lowered shares of Adial Pharmaceuticals to a “buy” rating in a research report on Monday, June 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Adial Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $17.17.

View Our Latest Research Report on ADIL

Hedge Funds Weigh In On Adial Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ADIL. Armistice Capital LLC acquired a new position in shares of Adial Pharmaceuticals during the 4th quarter worth about $562,000. Citadel Advisors LLC acquired a new stake in Adial Pharmaceuticals in the 3rd quarter valued at approximately $51,000. Finally, Jane Street Group LLC grew its holdings in Adial Pharmaceuticals by 887.3% in the 4th quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock valued at $27,000 after buying an additional 109,500 shares during the last quarter. 16.41% of the stock is currently owned by institutional investors.

About Adial Pharmaceuticals

(Get Free Report)

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.

Featured Stories

Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.